CN101160294A - 抗癌和抗微生物的噁唑烷酮以及类似物 - Google Patents

抗癌和抗微生物的噁唑烷酮以及类似物 Download PDF

Info

Publication number
CN101160294A
CN101160294A CNA2006800120083A CN200680012008A CN101160294A CN 101160294 A CN101160294 A CN 101160294A CN A2006800120083 A CNA2006800120083 A CN A2006800120083A CN 200680012008 A CN200680012008 A CN 200680012008A CN 101160294 A CN101160294 A CN 101160294A
Authority
CN
China
Prior art keywords
compound
alkyl
substituted
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800120083A
Other languages
English (en)
Chinese (zh)
Inventor
文卡塔·拉米·雷迪·马歇尔拉
本杰明·尼尔科森
林剑声
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nereus Pharmaceuticals Inc
Original Assignee
Nereus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc filed Critical Nereus Pharmaceuticals Inc
Publication of CN101160294A publication Critical patent/CN101160294A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/40—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/04—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers
    • C07C257/06—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines without replacement of the other oxygen atom of the carboxyl group, e.g. imino-ethers having carbon atoms of imino-carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms, or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2006800120083A 2005-02-22 2006-02-22 抗癌和抗微生物的噁唑烷酮以及类似物 Pending CN101160294A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65560505P 2005-02-22 2005-02-22
US60/655,605 2005-02-22

Publications (1)

Publication Number Publication Date
CN101160294A true CN101160294A (zh) 2008-04-09

Family

ID=36580024

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800120083A Pending CN101160294A (zh) 2005-02-22 2006-02-22 抗癌和抗微生物的噁唑烷酮以及类似物

Country Status (14)

Country Link
US (3) US7378530B2 (https=)
EP (1) EP1856066B1 (https=)
JP (1) JP2008531573A (https=)
KR (1) KR20070106578A (https=)
CN (1) CN101160294A (https=)
AT (1) ATE503748T1 (https=)
AU (1) AU2006216708A1 (https=)
BR (1) BRPI0607974A2 (https=)
CA (1) CA2597667A1 (https=)
DE (1) DE602006020992D1 (https=)
IL (1) IL185266A0 (https=)
MX (1) MX2007009990A (https=)
WO (1) WO2006091669A1 (https=)
ZA (1) ZA200707855B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781256A (zh) * 2012-10-29 2015-07-15 霍夫曼-拉罗奇有限公司 3,4-双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US10556874B2 (en) * 2015-07-03 2020-02-11 Bayer Cropscience Aktiengesellschaft N-(1,3,4-oxadiazol-2-yl)aryl carboxamide derivatives with herbicidal action
AU2016290425A1 (en) * 2015-07-03 2018-01-18 Bayer Cropscience Aktiengesellschaft N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives with herbicidal action
US10822315B2 (en) 2016-08-22 2020-11-03 North Carolina State University 5-benzylidene-4-oxazolidinones
WO2018039242A1 (en) 2016-08-22 2018-03-01 North Carolina State University 4-oxazolidinone antimicrobial agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2915527A (en) * 1959-12-01 Oxazolidone compounds and means for
US2971958A (en) * 1959-03-17 1961-02-14 Union Carbide Corp Cyanoethylated oxalactams
US3129222A (en) * 1960-12-01 1964-04-14 Merck & Co Inc 2, 2, 5-trisubstituted-4-oxazolidinone compounds
US3182063A (en) * 1961-03-06 1965-05-04 Warner Lambert Pharmaceutical Substituted 4-thiazolidinones and process therefor
DE1917615U (de) 1963-02-15 1965-06-10 Kloeckner Humboldt Deutz Ag Rotationskolbenmaschine.
DE1916715A1 (de) 1969-04-01 1970-10-08 Goedecke Ag Verfahren zur Herstellung von Oxazolidon-(4)-Derivaten
US4049816A (en) * 1975-03-24 1977-09-20 Beecham Group Limited Antiviral 2-amino-5-[1-(indol-3-yl)alkyl]-2-thiazolin-4-ones
US4584385A (en) * 1984-03-22 1986-04-22 Pfizer Inc. Antibacterial 2-amino-oxazolinones and process therefor
US4769232A (en) * 1984-03-22 1988-09-06 Pfizer Inc. Parenteral formulations of indolmycin
US4650512A (en) * 1984-09-27 1987-03-17 Stauffer Chemical Company Oxazolidone herbicides and methods of use
US4629794A (en) * 1985-02-04 1986-12-16 Pfizer Inc. Antibacterial 2-amino-oxazolinones and process therefor
US5677463A (en) 1996-11-20 1997-10-14 Abbott Laboratories Process for the preparation of 2-imino-5-phenyl-4 oxazolidinone and its intermediates
EP1103600A4 (en) * 1998-07-30 2002-11-06 Takeda Chemical Industries Ltd PROCESS FOR PRODUCING INDOLEMYCIN
US7378530B2 (en) * 2005-02-22 2008-05-27 Nereus Pharmaceuticals, Inc. Anti-cancer and anti-microbial 5-membered heterocyclic compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781256A (zh) * 2012-10-29 2015-07-15 霍夫曼-拉罗奇有限公司 3,4-双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途
CN104781256B (zh) * 2012-10-29 2017-09-29 霍夫曼-拉罗奇有限公司 3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途

Also Published As

Publication number Publication date
EP1856066A1 (en) 2007-11-21
US20080221183A1 (en) 2008-09-11
KR20070106578A (ko) 2007-11-01
JP2008531573A (ja) 2008-08-14
ATE503748T1 (de) 2011-04-15
BRPI0607974A2 (pt) 2010-08-17
AU2006216708A1 (en) 2006-08-31
IL185266A0 (en) 2008-02-09
US20080221182A1 (en) 2008-09-11
WO2006091669A1 (en) 2006-08-31
EP1856066B1 (en) 2011-03-30
US20060205799A1 (en) 2006-09-14
ZA200707855B (en) 2008-09-25
US7879892B2 (en) 2011-02-01
MX2007009990A (es) 2007-09-26
US7378530B2 (en) 2008-05-27
CA2597667A1 (en) 2006-08-31
DE602006020992D1 (de) 2011-05-12

Similar Documents

Publication Publication Date Title
US6972289B1 (en) Cell division inhibitor and a production method thereof
JPWO2001053290A1 (ja) 細胞分裂阻害剤及びその製造方法
CA2774367C (en) Compounds and therapeutic use thereof for protein kinase inhibition
CN101160294A (zh) 抗癌和抗微生物的噁唑烷酮以及类似物
US7098186B2 (en) Depsipeptide compound
WO2014034147A1 (ja) 新規光線過敏症抑制剤トレハンジェリン物質及びその製造法
CN106748939B (zh) 一类新型溴酚氨基硫脲类化合物及其制备和药物与用途
CN106188242A (zh) 一种新型环肽化合物在制备抑制结核杆菌的药物中的应用
JP4452787B2 (ja) 新規発酵生産物
JP3913542B2 (ja) 血管新生阻害作用を有する新規物質
JP2008514551A (ja) ジベンゾジアゼピノンアナログ、その製造方法及び医薬品としての使用
JP2002322182A (ja) 血管新生阻害作用を有するｒｋｂ−３５６４物質
JPH04321625A (ja) 抗腫瘍剤
JP4833461B2 (ja) 新規血管新生阻害剤
CN103275140A (zh) 十八碳双乙酰化一个双键内酯型槐糖脂及其应用
JPH0517419A (ja) 新規化合物および該化合物を有効成分とする抗腫瘍剤
JP2001011075A (ja) 新規ジオキソピペラジン誘導体
JP2003026696A (ja) 新規血管新生阻害剤
JPH01117830A (ja) 抗サイトメガロウイルス剤
JPH07233067A (ja) 新規抗真菌剤
JP2002060392A (ja) クルブラロール及びその製造方法
JPH0859462A (ja) アルドースレダクターゼ阻害剤
JPH09255680A (ja) スピロトリプロスタチン、その製造法、細胞周期阻害剤および抗腫瘍剤
JP2000007565A (ja) 抗腫瘍剤
JPH07223957A (ja) 制癌剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080409